213 related articles for article (PubMed ID: 21764518)
1. Targeting angiogenesis in ovarian cancer.
Schmitt J; Matei D
Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
[TBL] [Abstract][Full Text] [Related]
2. Overview of anti-angiogenic agents in development for ovarian cancer.
Burger RA
Gynecol Oncol; 2011 Apr; 121(1):230-8. PubMed ID: 21215996
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic drugs in ovarian cancer.
Markman M
Expert Opin Pharmacother; 2009 Oct; 10(14):2269-77. PubMed ID: 19671017
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic strategies, compounds, and early clinical results in breast cancer.
Morabito A; Sarmiento R; Bonginelli P; Gasparini G
Crit Rev Oncol Hematol; 2004 Feb; 49(2):91-107. PubMed ID: 15012971
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
9. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
Wachsberger P; Burd R; Dicker AP
Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
[TBL] [Abstract][Full Text] [Related]
10. The role of angiogenesis in solid tumours: an overview.
Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
12. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
13. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
14. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
RosanĂ² L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis as a strategic target for prostate cancer therapy.
Li Y; Cozzi PJ
Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
[TBL] [Abstract][Full Text] [Related]
18. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
19. The interaction of radiation therapy and antiangiogenic therapy.
O'Reilly MS
Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]